All peptides
ImmuneResearch Phase

Bursin

Subcutaneous injection
Written by Peptide Association Editorial TeamMedically reviewed by Ian Justl Ellis, MD, CPTLast reviewed Editorial policy

Overview

Bursin is a tripeptide (Lys-His-Gly) originally isolated from the bursa of Fabricius in avian species. It promotes B-lymphocyte differentiation and immunoglobulin production.

Mechanism of Action

The therapeutic rationale is to selectively enhance humoral immunity in conditions marked by antibody deficiency.

Research Summary & Key Findings

Preclinical avian and mammalian models have shown bursin-induced increases in B-cell maturation markers and serum immunoglobulin levels. Clinical translation has been hindered by limited potency in human systems and lack of controlled human trials.

Clinical Status

Research Phase

Bursin is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Subcutaneous injection

References

Primary literature

Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.

Related Peptides in Immune

Start Your Consultation

Get an AI-proposed Bursin protocol reviewed by a physician in our network.

Start Your Consultation

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Bursin.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.